These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31748266)

  • 1. Are Biotransformation Studies of Therapeutic Proteins Needed? Scientific Considerations and Technical Challenges.
    Schadt S; Hauri S; Lopes F; Edelmann MR; Staack RF; Villaseñor R; Kettenberger H; Roth AB; Schuler F; Richter WF; Funk C
    Drug Metab Dispos; 2019 Dec; 47(12):1443-1456. PubMed ID: 31748266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tools for predicting the PK/PD of therapeutic proteins.
    Diao L; Meibohm B
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1115-25. PubMed ID: 25936400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim.
    Niederalt C; Kuepfer L; Solodenko J; Eissing T; Siegmund HU; Block M; Willmann S; Lippert J
    J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):235-257. PubMed ID: 29234936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a PEARRL review.
    Loisios-Konstantinidis I; Paraiso RLM; Fotaki N; McAllister M; Cristofoletti R; Dressman J
    J Pharm Pharmacol; 2019 Apr; 71(4):699-723. PubMed ID: 30793317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
    Srinivas NR
    Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biotransformation and in vivo stability of protein biotherapeutics: impact on candidate selection and pharmacokinetic profiling.
    Hall MP
    Drug Metab Dispos; 2014 Nov; 42(11):1873-80. PubMed ID: 24947971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics.
    Fan J; de Lannoy IA
    Biochem Pharmacol; 2014 Jan; 87(1):93-120. PubMed ID: 24055064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
    Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T
    J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling.
    Ploeger BA; van der Graaf PH; Danhof M
    Drug Metab Pharmacokinet; 2009; 24(1):3-15. PubMed ID: 19252332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological considerations for predicting PK/PD at the site of action for therapeutic proteins.
    Wang W; Zhou H
    Drug Discov Today Technol; 2016; 21-22():35-39. PubMed ID: 27978986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of pharmacokinetic-pharmacodynamic relationships in drug development].
    Bellissant E; Courcier-Duplantier S; Blin O;
    Therapie; 2002; 57(4):347-57. PubMed ID: 12422555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging siRNA Design Principles and Consequences for Biotransformation and Disposition in Drug Development.
    Humphreys SC; Thayer MB; Campbell J; Chen WLK; Adams D; Lade JM; Rock BM
    J Med Chem; 2020 Jun; 63(12):6407-6422. PubMed ID: 32352779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.
    Colburn WA; Lee JW
    Clin Pharmacokinet; 2003; 42(12):997-1022. PubMed ID: 12959633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative pharmacokinetics and pharmacodynamics of the advanced Retinol-Binding Protein 4 antagonist in dog and cynomolgus monkey.
    Racz B; Varadi A; Pearson PG; Petrukhin K
    PLoS One; 2020; 15(1):e0228291. PubMed ID: 31978148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters.
    Smit C; De Hoogd S; Brüggemann RJM; Knibbe CAJ
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):275-285. PubMed ID: 29431542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins.
    Mahmood I; Green MD
    Clin Pharmacokinet; 2005; 44(4):331-47. PubMed ID: 15828849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioanalytical challenges and unique considerations to support pharmacokinetic characterization of bispecific biotherapeutics.
    Ma M; Colletti K; Yang TY; Leung S; Pederson S; Hottenstein CS; Xu X; Warrino D; Wakshull E
    Bioanalysis; 2019 Mar; 11(5):427-435. PubMed ID: 30887822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition and interaction of biotherapeutics in pediatric populations.
    Yanni S
    Curr Drug Metab; 2012 Sep; 13(7):882-900. PubMed ID: 22475271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J; Green AR
    J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.